Related Experiment Video
Updated: Nov 10, 2025
An Orthotopic Resectional Mouse Model of Pancreatic Cancer
Published on: September 24, 2020
A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
Yangbing Jin1,2, Zehui Zhang1,2, Siyi Zou1,2
1Department of General Surgery, Pancreatic Disease Center, Research Institute of Pancreatic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated death in the United States and has a 5-year survival rate of <4%. Although much effort has been invested in the research and development of pancreatic cancer drugs over the past 30 years, due to the lack of effective targetable carcinogenic drivers, no new targeted therapies that can improve patient prognosis have been approved for clinical use. SHR-A1403 is a new c-mesenchymal-epithelial transition factor (c-MET) antibody-drug conjugate that can be used for the targeted treatment of PDAC with high c-MET expression. This study reports for the first time the application prospects of SHR-A1403 in preclinical models of PDAC. SHR-A1403 significantly inhibited the proliferation, migration, and invasion of pancreatic cancer cells and induced cell cycle arrest and apoptosis. These changes were caused by inhibition of intracellular cholesterol biosynthesis by SHR-A1403. Therefore, targeting c-MET through SHR-A1403 showed strong preclinical anti-tumour efficacy in pancreatic cancer. Our work suggests the potential application of c-MET-targeted antibody-drug conjugate treatment for PDAC in clinical practise.
Insights
Pancreatic cancer treatment shows promise with SHR-A1403, a new antibody-drug conjugate targeting c-MET. This therapy effectively inhibited cancer cell growth and induced apoptosis in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a poor prognosis.
- Limited success in developing targeted therapies for PDAC due to lack of effective drivers.
- c-mesenchymal-epithelial transition factor (c-MET) is a potential target in PDAC.
Purpose of the Study:
- To evaluate the preclinical application and anti-tumour efficacy of SHR-A1403, a novel c-MET antibody-drug conjugate, in pancreatic cancer.
- To investigate the mechanism of action of SHR-A1403 in PDAC models.
Main Methods:
- Utilized preclinical models of pancreatic ductal adenocarcinoma (PDAC).
- Administered SHR-A1403, a c-MET antibody-drug conjugate.
- Assessed effects on cancer cell proliferation, migration, invasion, cell cycle, and apoptosis.
- Investigated the impact on intracellular cholesterol biosynthesis.
Main Results:
- SHR-A1403 significantly inhibited proliferation, migration, and invasion of pancreatic cancer cells.
- The drug induced cell cycle arrest and apoptosis in PDAC cells.
- SHR-A1403's efficacy was linked to the inhibition of intracellular cholesterol biosynthesis.
Conclusions:
- SHR-A1403 demonstrates strong preclinical anti-tumour activity against pancreatic cancer.
- Targeting c-MET with SHR-A1403 shows potential for clinical application in PDAC treatment.
- Inhibition of cholesterol biosynthesis is a key mechanism for SHR-A1403's efficacy.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
